Within the Carl Zeiss Meditec medical technology group, the business of eye lasers, diagnostic devices and surgical microscopes continues to thrive. However, in TecDax in Jena, the strong euro is synonymous with success – as with many German export-oriented companies. In the first nine months of the 2017/18 fiscal year, the company was able to increase sales by 7.1% year-over-year to € 926.3 million. Without the currency effect, there would have been a much larger advantage of just under 12%, as Carl Zeiss Meditec announced to Jena on Friday.
In the US market, where the company recorded the strongest growth, growth was more than offset by unfavorable currency effects. Profit before interest and taxes (EBIT) increased slightly from 132.6 million euros the previous year to 134.8 million euros. The bottom line, however, is that the profit fell from 92.5 to just under 82 million euros.
The year before, however, a special effect of a sale had increased the surplus. The group had already raised its turnover targets in early July to provide preliminary sales figures, they should now be in a range of 1.25 to 1.3 billion euros.